Intellia Therapeutics, Inc. (NTLA)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 25M 50M 75M Q4 '17: 26.1M Q1 '18: 27.4M Q2 '18: 29.1M Q3 '18: 29.2M Q4 '18: 30.4M Q1 '19: 33.4M Q2 '19: 36.8M Q3 '19: 40M Q4 '19: 43.1M Q1 '20: 45.6M Q2 '20: 50.7M Q3 '20: 62.3M Q4 '20: 58M Q1 '21: 51.5M Q2 '21: 41.8M Q3 '21: 26.8M Q4 '21: 33.1M Q1 '22: 37.9M Q2 '22: 45.3M Q3 '22: 51.4M Q4 '22: 52.1M Q1 '23: 53.5M Q2 '23: 53M Q3 '23: 51.8M Q4 '23: 38.2M Q1 '24: 54.5M Q2 '24: 47.9M Q3 '24: 45M Q4 '24: 57.9M Q1 '25: 45.6M Q2 '25: 52.9M Q3 '25: 57.5M Q4 '25: 67.7M Q1 '26: 66.1M Q2 '26: 59.5M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

0 15M 30M 45M Q2 '19: 36.8M Q3 '19: 40M Q4 '19: 43.1M Q2 '19 Q3 '19 Q4 '19

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income TTM

-600M -400M -200M 0 200M 400M 600M Q4 '15: -13.4M Q1 '16: -18.9M Q2 '16: -22.4M Q3 '16: -26.8M Q4 '16: -32.2M Q1 '17: -38.4M Q2 '17: -47.5M Q3 '17: -55.7M Q4 '17: -69.6M Q1 '18: -79M Q2 '18: -86.6M Q3 '18: -94.8M Q4 '18: -90.9M Q1 '19: -92.2M Q2 '19: -96.1M Q3 '19: -97.3M Q4 '19: -106.4M Q1 '20: -115.6M Q2 '20: -121.2M Q3 '20: -124M Q4 '20: -136.6M Q1 '21: -150M Q2 '21: -185.9M Q3 '21: -229.8M Q4 '21: -267.9M Q1 '22: -365.7M Q2 '22: -395M Q3 '22: -428.5M Q4 '22: -458.2M Q1 '23: -425.9M Q2 '23: -459.9M Q3 '23: -485.5M Q4 '23: -515.3M Q1 '24: -517.3M Q2 '24: -524M Q3 '24: -537.7M Q4 '24: -534.3M Q1 '25: -541.1M Q2 '25: -512M Q3 '25: -478.7M Q4 '25: -441M Q1 '26: -420.7M Q2 '26: -423.5M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Net Income TTM

-600M -400M -200M 0 200M 400M 600M Q4 '15: -12.4M Q1 '16: -18M Q2 '16: -21.9M Q3 '16: -26.3M Q4 '16: -31.6M Q1 '17: -37.6M Q2 '17: -46.3M Q3 '17: -54.1M Q4 '17: -67.5M Q1 '18: -76.3M Q2 '18: -82.9M Q3 '18: -90.2M Q4 '18: -85.3M Q1 '19: -85.9M Q2 '19: -89.4M Q3 '19: -90.3M Q4 '19: -99.5M Q1 '20: -109.4M Q2 '20: -116.1M Q3 '20: -120.3M Q4 '20: -134.2M Q1 '21: -148.6M Q2 '21: -185M Q3 '21: -228.8M Q4 '21: -267.9M Q1 '22: -368.6M Q2 '22: -400.4M Q3 '22: -442M Q4 '22: -474.2M Q1 '23: -430.4M Q2 '23: -453.4M Q3 '23: -462.4M Q4 '23: -481.2M Q1 '24: -485.5M Q2 '24: -508.8M Q3 '24: -522.3M Q4 '24: -519M Q1 '25: -525.9M Q2 '25: -480.2M Q3 '25: -445.8M Q4 '25: -412.7M Q1 '26: -394.6M Q2 '26: -400M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Cost of Revenue TTM

0 Q2 '19: 0 Q3 '19: 0 Q4 '19: 0 Q2 '19 Q3 '19 Q4 '19

Operating Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q4 '15: -1.8M Q1 '16: -16M Q2 '16: 49.4M Q3 '16: 45M Q4 '16: 36.1M Q1 '17: 34.1M Q2 '17: -49.1M Q3 '17: -58.4M Q4 '17: -65.3M Q1 '18: -71.6M Q2 '18: -78.5M Q3 '18: -74M Q4 '18: -61.3M Q1 '19: -64.9M Q2 '19: -70.1M Q3 '19: -83.1M Q4 '19: -103.2M Q1 '20: -120.3M Q2 '20: -35.2M Q3 '20: -38.3M Q4 '20: -49.9M Q1 '21: -63.7M Q2 '21: -174.1M Q3 '21: -210.6M Q4 '21: -225M Q1 '22: -252.5M Q2 '22: -284.6M Q3 '22: -298.1M Q4 '22: -333.3M Q1 '23: -362.8M Q2 '23: -368M Q3 '23: -390.9M Q4 '23: -394.1M Q1 '24: -405.4M Q2 '24: -373.3M Q3 '24: -356.7M Q4 '24: -348.9M Q1 '25: -377.1M Q2 '25: -418.6M Q3 '25: -410.6M Q4 '25: -394.7M Q1 '26: -363.2M Q2 '26: -346.6M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Free Cash Flow TTM

-450M -300M -150M 0 150M 300M 450M Q4 '15: -4.3M Q1 '16: -19.1M Q2 '16: 45.8M Q3 '16: 41.4M Q4 '16: 29.9M Q1 '17: 24.8M Q2 '17: -58.5M Q3 '17: -69.5M Q4 '17: -75.4M Q1 '18: -79.4M Q2 '18: -85.9M Q3 '18: -81.2M Q4 '18: -67.6M Q1 '19: -71M Q2 '19: -76.2M Q3 '19: -88.9M Q4 '19: -110M Q1 '20: -126.4M Q2 '20: -41.4M Q3 '20: -43.5M Q4 '20: -53.5M Q1 '21: -68.9M Q2 '21: -181.2M Q3 '21: -221.5M Q4 '21: -237.8M Q1 '22: -264.2M Q2 '22: -297.4M Q3 '22: -310.6M Q4 '22: -346.8M Q1 '23: -378.8M Q2 '23: -384.3M Q3 '23: -407.3M Q4 '23: -408.1M Q1 '24: -418.1M Q2 '24: -382.7M Q3 '24: -363.1M Q4 '24: -354.7M Q1 '25: -381.2M Q2 '25: -421.8M Q3 '25: -412.6M Q4 '25: -395.9M Q1 '26: -363.6M Q2 '26: -348.7M Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 50M 100M 150M Q2 '21: 68.2M Q3 '21: 73.7M Q1 '22: 74.8M Q2 '22: 75.8M Q3 '22: 76M Q1 '23: 87.8M Q2 '23: 88.2M Q3 '23: 88.6M Q1 '24: 95.5M Q2 '24: 97M Q3 '24: 101M Q1 '25: 103.5M Q2 '25: 103.7M Q3 '25: 110.2M Q1 '26: 118.5M Q2 '26: 133.5M Q3 '21 Q2 '22 Q1 '23 Q3 '23 Q2 '24 Q1 '25 Q3 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-45.00 -30.00 -15.00 0.00 15.00 30.00 45.00 Q4 '15: -23.06 Q1 '16: -32.10 Q2 '16: -30.09 Q3 '16: -20.04 Q4 '16: -10.78 Q1 '17: -1.25 Q2 '17: -1.34 Q3 '17: -1.56 Q4 '17: -1.86 Q1 '18: -2.01 Q2 '18: -2.08 Q3 '18: -2.17 Q4 '18: -1.99 Q1 '19: -1.97 Q2 '19: -2.01 Q3 '19: -1.97 Q4 '19: -2.11 Q1 '20: -2.25 Q2 '20: -2.30 Q3 '20: -2.28 Q4 '20: -2.40 Q1 '21: -2.46 Q2 '21: -2.86 Q3 '21: -3.36 Q4 '21: -3.77 Q1 '22: -5.04 Q2 '22: -5.36 Q3 '22: -5.88 Q4 '22: -6.16 Q1 '23: -5.37 Q2 '23: -5.44 Q3 '23: -5.33 Q4 '23: -5.41 Q1 '24: -5.36 Q2 '24: -5.48 Q3 '24: -5.44 Q4 '24: -5.24 Q1 '25: -5.22 Q2 '25: -4.68 Q3 '25: -4.26 Q4 '25: -3.82 Q1 '26: -3.53 Q2 '26: -3.35 Q4 '15 Q2 '17 Q4 '18 Q2 '20 Q4 '21 Q2 '23 Q4 '24 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.